A2 Milk (ASX:A2M): New Formula For Success
Marc Kennis, January 15, 2022
Got milk? Why we are getting bullish on A2 Milk
The dogs of the ASX in 2021 had several names you can instantly think of – Nuix, Crown, AGL and perhaps – the worst of them all – A2 Milk (ASX:A2M).
The company is the subject of two class action claims over its consistent downgrades in earnings. In late October during an investor day, Chief executive David Bortolussi outlined his new plan to overhaul its China strategy, which meant operating margins will be sacrificed for revenue growth.
What are the Best ASX Stocks to invest in right now?
Check our buy/sell tips on the top Stocks in ASX
More recently, chairman David Hearn responded to shareholders’ concerns by saying the various updates were based on “the best information we had at the time.”
Enter Stuart Roberts from Stocks Down Under who says the worst days are behind us. Why? Listen in for his reasoning.
Disclosure: Stocks Down Under directors own shares in A2M.
Want to stay up-to-date on ASX-listed stocks?
Make sure you subscribe to Stocks Down Under today!
Get a 14-day FREE TRIAL to CONCIERGE now
No credit card needed and the trial expires automatically.
Frequently Asked Questions about A2 Milk
- Is A2 Milk an Australian company?
No, A2M was founded in New Zealand, but has its primary stock market listing on the Australian ASX. It also operates a number of farms in Australia.
- What is so special about a2 milk?
A2 milk only contains the A2 beta-casein protein, not the A1 protein. A1 milk can potentially negatively affect the immunohormonal system and contribute to type 1 diabetes or heart disease. So, A2 milk is healthier for you.
- Does A2M pay a dividend?
No, A2M does not pay a dividend, but instead reinvests funds in the growth of its business.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Analysts aren’t optimistic about iron ore prices in 2025, will they be right and what will it mean for iron ore stocks?
In which direction will iron ore prices in 2025 go? Chinese trade data would suggest upwards, and indeed prices jumped…
Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025
Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate…
Findi (ASX:FND): Its quadrupled in 12 months off the back of financial services in India
Until Findi (ASX:FND) came along, there were practically no ASX companies making money from India (or at least not many…